Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis

Annals of Family Medicine

Volumn 13, Issue 1, 2015, Pages 69-79

  Linde, Klaus ^a   Kriston, Levente ^b   Rücker, Gerta ^c   Jamil, Susanne ^a   Schumann, Isabelle ^a   Meissner, Karin ^a,d   Sigterman, Kirsten ^a   Schneider, Antonius ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidepressive agents; Depression; Depressive disorders; Primary health care; Review; Systematic

Indexed keywords

ANTIDEPRESSANT AGENT;

DEPRESSIVE DISORDER; HUMAN; META ANALYSIS; PATIENT ATTITUDE; PRIMARY HEALTH CARE; PROCEDURES; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 84920982677     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1687     Document Type: Article

References (38)

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al; WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581-2590.
2. Bijl RV, Ravelli A. Psychiatric morbidity, service use, and need for care in the general population: results of The Netherlands Mental Health Survey and Incidence Study. Am J Public Health. 2000;90(4):602-607.
3. Peveler R, Kendrick T. Treatment delivery and guidelines in primary care. Br Med Bull. 2001;57:193-206.
4. Schwenk TL, Coyne JC, Fechner-Bates S. Differences between detected and undetected patients in primary care and depressed psychiatric patients. Gen Hosp Psychiatry. 1996;18(6):407-415.
5. Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med. 1995;4(2):99-105.
6. Williamson PS, Yates WR. The initial presentation of depression in family practice and psychiatric outpatients. Gen Hosp Psychiatry. 1989;11(3):188-193, discussion 216 -221.
7. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med. 1993; 153(21):2474-2480.
8. Trangle M, Dieperink B, Gabert T, et al. Major depression in adults in primary care. Bloomington, MN: Institute for Clinical Systems Improvement; 2012.
9. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefts: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
10. Adli M, Hegerl U. Do we underestimate the benefts of antidepres-sants? Lancet. 2014;383(9926):1361-1362.
11. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. 2009; (3):CD007954.
12. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med. 2005;3(5):449-456.
13. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic anti-depressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326(7397):1014.
14. Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000;108(1):54-64.
15. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897-900.
16. Linde K, Schumann I, Meissner K, et al. Treatment of depressive disorders in primary care—protocol of a multiple treatment systematic review of randomized controlled trials. BMC Fam Pract. 2011;12:127.
17. Linde K, Sigterman K, Kriston L, et al. Effectiveness of psychological treatment for depressive disorders in primary care: systematic review and meta-analysis. Ann Fam Med. 2014;12(6):56-68.
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Updated March 2011. London, England: The Cochrane Collaboration; 2008. http://handbook.cochrane.org.
19. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW: S3-Leitlinie/Nationale Versorgungsleitlinie Uni-polare Depression - Langfassung. Berlin, Düsseldorf: DGPPN, ÄZQ, AWMF; 2009. http://www.leitlinien.de/nvl/depression/.
20. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol. 2005;20(1):49-52.
21. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607-617.
22. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641-656.
23. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity—subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33(5):618-640.
24. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reup-take inhibitor controlled trials. BMJ. 2010;341:c4737.
25. Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008;(4):CD000448.
26. Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf. 2004;27(11):773-797.
27. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
28. Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 2012;7(8):e42003.
29. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-750.
30. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155 (11):772-785.
31. National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults. http://www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf. Updated 2010.
32. Lam RW, Kennedy SH, Grigoriadis S, et al; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26-S43.
33. Ravindran AV, Lam RW, Filteau MJ, et al; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord. 2009;117(Suppl 1):S54-S64.
34. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its infuence on apparent effcacy. N Engl J Med. 2008;358(3):252-260.
35. Fountoulakis KN, Veroniki AA, Siamouli M, Möller HJ. No role for initial severity on the effcacy of antidepressants: results of a multi-meta-analysis. Ann Gen Psychiatry. 2013;12 (1): 26.
36. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
37. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fuoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572-579.
38. Cuijpers P, Turner EH, Koole SL, van Dijke A, Smit F. What is the threshold for a clinically relevant effect? The case of major depressive disorders. Depress Anxiety. 2014;31(5):374-378.